1. Home
  2. RMCO vs TELA Comparison

RMCO vs TELA Comparison

Compare RMCO & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

HOLD

Current Price

$2.62

Market Cap

35.3M

Sector

Miscellaneous

ML Signal

HOLD

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$0.88

Market Cap

41.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
TELA
Founded
2021
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.3M
41.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RMCO
TELA
Price
$2.62
$0.88
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
N/A
$2.00
AVG Volume (30 Days)
36.9K
127.3K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
37.59
EPS
N/A
N/A
Revenue
N/A
$80,275,000.00
Revenue This Year
$209.10
$10.23
Revenue Next Year
$133.33
$14.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.84
52 Week Low
$1.05
$0.50
52 Week High
$5.00
$2.19

Technical Indicators

Market Signals
Indicator
RMCO
TELA
Relative Strength Index (RSI) 51.06 52.24
Support Level $1.94 $0.67
Resistance Level $3.14 $1.24
Average True Range (ATR) 0.35 0.11
MACD 0.05 -0.01
Stochastic Oscillator 75.86 52.26

Price Performance

Historical Comparison
RMCO
TELA

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: